Evidence map›Paper›PMID 25191529›Full record

ArticleThe open ophthalmology journal2014

Glycolysis in patients with age-related macular degeneration.

Kanako Yokosako, Tatsuya Mimura, Hideharu Funatsu, Hidetaka Noma, Mari Goto, Yuko Kamei, Aki Kondo, Masao Matsubara

Open access · diamondAbstract read
In one paragraph

Article in The open ophthalmology journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Small-Molecule Inhibition of Glucose Transporters GLUT-1-4.Chembiochem : a European journal of chemical biology · 2020
    Review
  12. Article
  13. Observational
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kanako YokosakoDepartment of Ophthalmology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
Tatsuya MimuraDepartment of Ophthalmology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
Hideharu FunatsuDepartment of Ophthalmology, Yachiyo Medical Center, Tokyo Women's Medical University, Chiba, Japan.
Hidetaka NomaDepartment of Ophthalmology, Hachioji Medical Center, Tokyo Medical University, Tokyo, Japan.
Mari GotoDepartment of Ophthalmology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
Yuko KameiDepartment of Ophthalmology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
Aki KondoDepartment of Ophthalmology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
Masao MatsubaraDepartment of Ophthalmology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
Tokyo Women's Medical University Adachi Medical Center · JPTokyo Medical University Hachioji Medical Center · JPTokyo Women's Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRetinal adenosine triphosphate is mainly produced via glycolysis, so inhibition of glycolysis may promote the onset and progression of age-related macular degeneration (AMD). When glycolysis is inhibited, pyruvate is metabolized by lactic acid fermentation instead of entering the mitochondrial tricarboxylic acid (TCA) cycle. We measured urinary pyruvate and lactate levels in patients with AMD.

methodsEight patients with typical AMD (tAMD group) and 9 patients with polypoidal choroidal vasculopathy (PCV group) were enrolled. Urinary levels of pyruvate, lactate, α-hydroxybutyrate, and β-hydroxybutyrate were measured in all patients.

resultsThe mean urinary levels of pyruvate and lactate were 8.0 ± 2.8 and 7.5 ± 8.3 μg/mg creatinine (reference values: 0.5-6.6 and 0.0-1.6), respectively, with the mean increase over the reference value being 83.6 ± 51.1% and 426.5 ± 527.8%, respectively. In 12 patients (70.6%), the lactate/pyruvate ratio was above the reference range. Urinary levels of α-hydroxybutyrate and β-hydroxybutyrate were decreased by -31.9 ± 15.2% and -33.1 ± 17.5% compared with the mean reference values. There were no significant differences of any of these glycolysis metabolites between the tAMD and PCV groups. Multivariate analysis revealed that none of the variables tested, including patient background factors (age, hypertension, diabetes, hyperlipidemia, cerebrovascular disease, alcohol, smoking, visual acuity, and AMD phenotype), were significantly associated with the lactate/pyruvate ratio.

conclusionA high lactate/pyruvate ratio is a well-known marker of mitochondrial impairment, and it indicates poor oxidative function in AMD. Our results suggest that increased lactate levels may be implicated in the pathogenesis of AMD.

Indexed as

Age-related macular degenerationglycolysisketone bodylactatepyruvate.

Identifiers

PMID25191529
PMCPMC4150380
OpenAlexW2130213418

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.